Investigational Drug Information for Homoharringtonine
✉ Email this page to a colleague
What is the development status for investigational drug Homoharringtonine?
Homoharringtonine is an investigational drug.
There have been 37 clinical trials for Homoharringtonine.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2019.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Leukemia, and Leukemia, Myeloid, Acute. The leading clinical trial sponsors are National Cancer Institute (NCI), The First Affiliated Hospital of Soochow University, and M.D. Anderson Cancer Center.
There are four hundred and five US patents protecting this investigational drug and zero international patents.
Summary for Homoharringtonine
| US Patents | 405 |
| International Patents | 4,819 |
| US Patent Applications | 1,494 |
| WIPO Patent Applications | 1,243 |
| Japanese Patent Applications | 309 |
| Clinical Trial Progress | Phase 2 (2019-12-01) |
| Vendors | 45 |
Recent Clinical Trials for Homoharringtonine
| Title | Sponsor | Phase |
|---|---|---|
| Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | N/A |
| Study of Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients | The First Affiliated Hospital of Soochow University | N/A |
| Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML | The First Affiliated Hospital of Soochow University | Phase 2/Phase 3 |
Clinical Trial Summary for Homoharringtonine
Top disease conditions for Homoharringtonine
Top clinical trial sponsors for Homoharringtonine
US Patents for Homoharringtonine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Homoharringtonine | ⤷ Sign Up | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Sign Up |
| Homoharringtonine | ⤷ Sign Up | MCL-1 as a therapeutic target in SCFFBW7 deficient neoplasm | Beth Israel Deaconess Medical Center, Inc. (Boston, MA) | ⤷ Sign Up |
| Homoharringtonine | ⤷ Sign Up | Non-fouling, anti-microbial, anti-thrombogenic graft compositions | ARROW INTERNATIONAL, INC. (Wayne, PA) | ⤷ Sign Up |
| Homoharringtonine | ⤷ Sign Up | Aryl-cyanoguanidine compounds | Bayer Pharma Aktiengesellschaft (Berlin, DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Homoharringtonine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Homoharringtonine | Australia | AU2014348657 | 2033-11-13 | ⤷ Sign Up |
| Homoharringtonine | Australia | AU2017245411 | 2033-11-13 | ⤷ Sign Up |
| Homoharringtonine | Australia | AU2019246853 | 2033-11-13 | ⤷ Sign Up |
| Homoharringtonine | Brazil | BR112016010716 | 2033-11-13 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
